1. Home
  2. AIOT vs DSGN Comparison

AIOT vs DSGN Comparison

Compare AIOT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PowerFleet Inc.

AIOT

PowerFleet Inc.

HOLD

Current Price

$3.27

Market Cap

683.8M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$14.24

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIOT
DSGN
Founded
1993
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
683.8M
819.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AIOT
DSGN
Price
$3.27
$14.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$10.33
$15.25
AVG Volume (30 Days)
1.3M
553.4K
Earning Date
06-15-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.46
N/A
Revenue Next Year
$9.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.78
$3.31
52 Week High
$5.98
$17.25

Technical Indicators

Market Signals
Indicator
AIOT
DSGN
Relative Strength Index (RSI) 48.79 53.55
Support Level $2.82 $9.25
Resistance Level $3.39 $17.25
Average True Range (ATR) 0.14 1.23
MACD -0.00 -0.01
Stochastic Oscillator 56.32 30.36

Price Performance

Historical Comparison
AIOT
DSGN

About AIOT PowerFleet Inc.

PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: